On the other hand, pharmacological and genetic targeting of the HMTase G9a/GLP was shown to be efficient in slowing down AML cell proliferation in a mouse model and human AML cell lines [26, 28] thus making these HMTases potential targets for epigenetic therapy of AML. The gene discussed is EHMT2; the disease is acute myeloid leukemia.